A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Sulfacytine
Temafloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Temafloxacin.
Sulfacytine
Nicorandil
Nicorandil may increase the hypotensive activities of Canagliflozin.
Sulfacytine
Aripiprazole lauroxil
Aripiprazole lauroxil may increase the hypotensive activities of Canagliflozin.
Sulfacytine
Fosphenytoin
The serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.
Sulfacytine
Azosemide
The risk or severity of hypotension can be increased when Canagliflozin is combined with Azosemide.
Sulfacytine
Piretanide
The risk or severity of hypotension can be increased when Canagliflozin is combined with Piretanide.
Sulfacytine
Cilazaprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Cilazaprilat.
Sulfacytine
Quinaprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Quinaprilat.
Sulfacytine
Perindoprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Perindoprilat.
Sulfacytine
Ramiprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Ramiprilat.
Sulfacytine
Fosinoprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Fosinoprilat.
Sulfacytine
Benazeprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Benazeprilat.
Sulfacytine
Delapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Delapril.
Sulfacytine
Zofenopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Zofenopril.
Sulfacytine
Imidapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Imidapril.
Sulfacytine
Enalaprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Enalaprilat.
Sulfacytine
Quinoline Yellow WS
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Quinoline Yellow WS.
Sulfacytine
Moexiprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Moexiprilat.
Sulfacytine
Trandolaprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Trandolaprilat.
Sulfacytine
Candesartan
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Candesartan.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3